Shire

Pharma AbbVie, Shire investors agree to settle lawsuit over scuttled tax-inversion deal
Pharma AbbVie, Shire investors agree to settle lawsuit over scuttled tax-inversion deal
Fierce Pharma
AbbVie
Shire
taxes
tax inversions
M&A
Flag link:
14 Drugs Earn Billions for These Massachusetts Biotechs
14 Drugs Earn Billions for These Massachusetts Biotechs
BioSpace
Massachusetts
Boston
Biogen
Tecfidera
Benepali
Shire
Takeda
Vyvanse
Vertex Pharmaceuticals
Orkambi
Kalydeco
Alexion
Soliris
Strensiq
Sanofi Genzyme
Lantus
Ironwood Pharmaceuticals
Linzess
Flag link:
Case Study: How Shire improved its time-to-market
Case Study: How Shire improved its time-to-market
Pharmaforum
Shire
drug development
time-to-market
Flag link:
Takeda mulling sale of emerging market drugs – report
Takeda mulling sale of emerging market drugs – report
Pharmaforum
Takeda
Shire
M&A
emerging markets
Flag link:
Takeda’s Shire takeover could herald new era of pharma M&A
Takeda’s Shire takeover could herald new era of pharma M&A
Pharmaforum
M&A
Takeda
Shire
taxes
Pfizer
Flag link:
With mega merger season in full swing, Takeda officially swallows Shire
With mega merger season in full swing, Takeda officially swallows Shire
Endpoints
Takeda
Shire
M&A
Flag link:
Takeda builds arsenal for immuno-oncology research, creates cell therapy group
Takeda builds arsenal for immuno-oncology research, creates cell therapy group
Endpoints
Takeda
immuno-oncology
cell therapy
Shire
Flag link:
Shire gears up to battle Allergan's Linzess with new constipation drug Motegrity
Shire gears up to battle Allergan's Linzess with new constipation drug Motegrity
Fierce Pharma
Takeda
Shire
Allergan
chronic idiopathic constipation
Motegrity
Flag link:
A last-ditch effort to derail Takeda’s $62B Shire buyout goes down in flames
A last-ditch effort to derail Takeda’s $62B Shire buyout goes down in flames
Endpoints
Takeda
Shire
M&A
Flag link:
Takeda Acquisition Of Shire May Bode Well For R&D Staff
Takeda Acquisition Of Shire May Bode Well For R&D Staff
Forbes
Shire
Takeda
R&D
M&A
Flag link:
Takeda ready to dismiss assets for a total $10bn
Takeda ready to dismiss assets for a total $10bn
GoinPharma
Takeda
Shire
M&A
Flag link:
Takeda could rack up $10B in selloffs after controversial Shire buyout: report
Takeda could rack up $10B in selloffs after controversial Shire buyout: report
Fierce Pharma
Takeda
Shire
M&A
shareholders
Flag link:
Takeda clears final regulatory hurdle to completing its $62B Shire deal. Now only one obstacle remains
Takeda clears final regulatory hurdle to completing its $62B Shire deal. Now only one obstacle remains
Endpoints
Takeda
shareholders
Japan
M&A
Shire
Europe
Flag link:
Takeda investors mount last-minute effort to stymie Shire deal: FT
Takeda investors mount last-minute effort to stymie Shire deal: FT
Fierce Pharma
Takeda
Shire
shareholders
M&A
Flag link:
With the $62B Shire buyout on track, Takeda plans to debut the newly merged company at JPMorgan
With the $62B Shire buyout on track, Takeda plans to debut the newly merged company at JPMorgan
Endpoints
Takeda
Shire
M&A
Christophe Weber
Flag link:
Exclusive: Takeda to win EU approval for US$62 billion Shire deal - sources
Exclusive: Takeda to win EU approval for US$62 billion Shire deal - sources
Channel News Asia
Takeda
Shire
M&A
Europe
Flag link:
Takeda CEO confident about Shire merger
Takeda CEO confident about Shire merger
Pharmaforum
Takeda
Shire
M&A
shareholders
Pharma CEOs
Christophe Weber
Flag link:
Positive quarter from Takeda, waiting for completion of Shire deal
Positive quarter from Takeda, waiting for completion of Shire deal
GoinPharma
Takeda
Shire
M&A
earnings
Flag link:
Takeda considering sale of OTC business in Europe ($11bn)
Takeda considering sale of OTC business in Europe ($11bn)
Bloomberg
Takeda
Shire
M&A
OTC
Flag link:
Takeda is ready to auction off a PhIII favorite at Shire to clear the last hurdles to a $62B buyout
Takeda is ready to auction off a PhIII favorite at Shire to clear the last hurdles to a $62B buyout
Enpoints
Takeda
Shire
inflammatory bowel disease
IBD
ulcerative colitis
Crohn's Disease
M&A
SHP647
Flag link:

Pages